Overview

Study of PWT33597 Mesylate in Subjects With Advanced Malignancies

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical effects of orally administered PWT33597 mesylate in subjects with advanced malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
Pathway Therapeutics, Inc.